Accession Number: | 0001562180-21-001909 |
Date: | 2021-03-01 |
Issuer: | SYNDAX PHARMACEUTICALS INC (SNDX) |
Original Submission Date: |
EGROS FABRICE
C/O SYNDAX PHARMACEUTICALS, INC.
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3
WALTHAM, MA 02451
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-03-01 | M | 10,167 | a | $6.35 | 26,167 | direct | ||
COMMON STOCK | 2021-03-01 | M | 74 | a | $7.20 | 26,241 | direct | ||
COMMON STOCK | 2021-03-01 | S | 10,167 | d | $24.31 | 16,074 | direct | ||
COMMON STOCK | 2021-03-01 | S | 74 | d | $24.31 | 16,000 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTIONS (RIGHT TO BUY) | 7.2 | 2021-03-01 | deemed execution date | M | 74 (d) | 2025-08-18 | common stock 0 | $7.20 | 0 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 6.35 | 2021-03-01 | deemed execution date | M | 10,167 (d) | 2024-12-18 | common stock 0 | $6.35 | 0 | direct |
ID | footnote |
---|---|
f1 | the sale reported in this form 4 was effected pursuant to a rule 10b5-1 plan adopted by the reporting person. following the sale reported in this form 4, the reporting person has a total of 106,926 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested. |
f2 | the sale prices ranged from $23.84 to $25.15. |
f3 | this option is fully vested. |